FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890625470> ?p ?o ?g. }

• W2890625470 endingPage "369" @default.
• W2890625470 startingPage "359" @default.
• W2890625470 abstract "Homeotransplantation of bones for replacement therapy have been demonstrated reliably in clinical data. However, human donor bones applicable for homeotransplantation are in short supply, which facilitates the search for suitable alternatives, such as xenografts grafts. The α-Gal antigen-related immune risk of xenografts directly affects the safety and effectiveness of the biomaterials and limits their applications in the clinic. The immune risk can be prevented by depletion or breaking anti-Gal antibody prior to transplant. Therefore, how to assess the immune risk of the bone substitutes and select the reliable animal research model become extremely important. In this study, we prepared lyophilized bone substitutes (T1) and Guanghao Biotech bone substitutes (T2, animal-derived biomaterials with α-Gal antigen decreased), aimed to assess the immune risk of xenografts bone substitutes on GGTA1 knockout mice. The α-Gal antigen contents of T1 and T2 were firstly detected by ELISA method in vitro. The bone substitutes were then implanted subcutaneously into GGTA1 knockout mice for 2, 4 and 12 weeks, respectively. The total serum antibody levels, anti-α-Gal antibody levels, inflammatory cytokine and splenic lymphocyte surface molecules were detected and histology analysis of skin and thymus were performed to systematically evaluate the immune response caused by the T1 and T2 bone substitutes in mice. In vitro results showed that the amount of α-Gal epitopes in T1 bone substitutes was significantly higher than T2 bone substitutes, and the clearance rate of α-Gal antigen in T2 bone substitutes achieved about 55.6%. Results of antibody level in vivo showed that the T1 bone substitutes group possessed significantly higher total IgG, IgM, IgA and anti-α-Gal IgG levels than T2 and control group, while T2 group showed no significant changes of these indexes compared with control. In terms of inflammatory cytokines, T1 bone substitutes showed evidently higher levels of IL-4, IL-12P70 and IL-10 than T2 and control, while T2 group was comparable to control. No changes in the levels of splenic lymphocyte surface molecules were found in the three groups (T1, T2 and control group) during the experimental periods. The pathological results demonstrated that the inflammatory response in T2 group was lighter than the T1 group, which was in accordance with the inflammatory cytokines levels. The above results indicated that the process of antigen removal effectively reduced the α-Gal antigens content in T2 bone substitutes, which caused little immune response in vivo and could be used as bone healing materials. This study also demonstrated that GGTA1 knockout mice can be used as a routine tool to assess the immune risk of animal-derived biomaterials." @default.
• W2890625470 created "2018-09-27" @default.
• W2890625470 creator A5020208004 @default.
• W2890625470 creator A5023239877 @default.
• W2890625470 creator A5032292565 @default.
• W2890625470 creator A5037843769 @default.
• W2890625470 creator A5043843718 @default.
• W2890625470 creator A5055320676 @default.
• W2890625470 creator A5067985443 @default.
• W2890625470 creator A5080664506 @default.
• W2890625470 date "2018-09-12" @default.
• W2890625470 modified "2023-10-13" @default.
• W2890625470 title "Xenogeneic bone matrix immune risk assessment using GGTA1 knockout mice" @default.
• W2890625470 cites W135037860 @default.
• W2890625470 cites W1830480933 @default.
• W2890625470 cites W1969358266 @default.
• W2890625470 cites W1972491174 @default.
• W2890625470 cites W1975198612 @default.
• W2890625470 cites W1988620887 @default.
• W2890625470 cites W1988672382 @default.
• W2890625470 cites W1990923023 @default.
• W2890625470 cites W2008565536 @default.
• W2890625470 cites W2009912209 @default.
• W2890625470 cites W2017280930 @default.
• W2890625470 cites W2025066164 @default.
• W2890625470 cites W2028913711 @default.
• W2890625470 cites W2056902283 @default.
• W2890625470 cites W2067384559 @default.
• W2890625470 cites W2071555784 @default.
• W2890625470 cites W2086783776 @default.
• W2890625470 cites W2098252984 @default.
• W2890625470 cites W2103797742 @default.
• W2890625470 cites W2115515184 @default.
• W2890625470 cites W2124483624 @default.
• W2890625470 cites W2127567785 @default.
• W2890625470 cites W2136750870 @default.
• W2890625470 cites W2146648455 @default.
• W2890625470 cites W2151173049 @default.
• W2890625470 cites W2171287700 @default.
• W2890625470 cites W2411444623 @default.
• W2890625470 cites W2609729296 @default.
• W2890625470 cites W2616296979 @default.
• W2890625470 cites W2735803903 @default.
• W2890625470 doi "https://doi.org/10.1080/21691401.2018.1493489" @default.
• W2890625470 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30207744" @default.
• W2890625470 hasPublicationYear "2018" @default.
• W2890625470 type Work @default.
• W2890625470 sameAs 2890625470 @default.
• W2890625470 citedByCount "14" @default.
• W2890625470 countsByYear W28906254702019 @default.
• W2890625470 countsByYear W28906254702020 @default.
• W2890625470 countsByYear W28906254702021 @default.
• W2890625470 countsByYear W28906254702022 @default.
• W2890625470 countsByYear W28906254702023 @default.
• W2890625470 crossrefType "journal-article" @default.
• W2890625470 hasAuthorship W2890625470A5020208004 @default.
• W2890625470 hasAuthorship W2890625470A5023239877 @default.
• W2890625470 hasAuthorship W2890625470A5032292565 @default.
• W2890625470 hasAuthorship W2890625470A5037843769 @default.
• W2890625470 hasAuthorship W2890625470A5043843718 @default.
• W2890625470 hasAuthorship W2890625470A5055320676 @default.
• W2890625470 hasAuthorship W2890625470A5067985443 @default.
• W2890625470 hasAuthorship W2890625470A5080664506 @default.
• W2890625470 hasBestOaLocation W28906254701 @default.
• W2890625470 hasConcept C126322002 @default.
• W2890625470 hasConcept C147483822 @default.
• W2890625470 hasConcept C150903083 @default.
• W2890625470 hasConcept C159654299 @default.
• W2890625470 hasConcept C170493617 @default.
• W2890625470 hasConcept C182704531 @default.
• W2890625470 hasConcept C195616568 @default.
• W2890625470 hasConcept C203014093 @default.
• W2890625470 hasConcept C207001950 @default.
• W2890625470 hasConcept C2780007613 @default.
• W2890625470 hasConcept C2911091166 @default.
• W2890625470 hasConcept C71924100 @default.
• W2890625470 hasConcept C86803240 @default.
• W2890625470 hasConcept C8891405 @default.
• W2890625470 hasConceptScore W2890625470C126322002 @default.
• W2890625470 hasConceptScore W2890625470C147483822 @default.
• W2890625470 hasConceptScore W2890625470C150903083 @default.
• W2890625470 hasConceptScore W2890625470C159654299 @default.
• W2890625470 hasConceptScore W2890625470C170493617 @default.
• W2890625470 hasConceptScore W2890625470C182704531 @default.
• W2890625470 hasConceptScore W2890625470C195616568 @default.
• W2890625470 hasConceptScore W2890625470C203014093 @default.
• W2890625470 hasConceptScore W2890625470C207001950 @default.
• W2890625470 hasConceptScore W2890625470C2780007613 @default.
• W2890625470 hasConceptScore W2890625470C2911091166 @default.
• W2890625470 hasConceptScore W2890625470C71924100 @default.
• W2890625470 hasConceptScore W2890625470C86803240 @default.
• W2890625470 hasConceptScore W2890625470C8891405 @default.
• W2890625470 hasFunder F4320321001 @default.
• W2890625470 hasFunder F4320321537 @default.
• W2890625470 hasIssue "sup3" @default.
• W2890625470 hasLocation W28906254701 @default.
• W2890625470 hasLocation W28906254702 @default.
• W2890625470 hasOpenAccess W2890625470 @default.

• next